SCHEMBL232139

SCHEMBL232139

c1[nH]nnc1N(c1c[nH]nn1)c1c[nH]nn1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL622400 1.00
SCHEMBL2226753 0.97
SCHEMBL3175727 0.76 ESR1 (0.33)
SCHEMBL2542826 0.71
SCHEMBL16921915 0.71 PDE10A (0.32)
SCHEMBL4724209 0.71
SCHEMBL4724056 0.69 HCAR3 (0.39)
SCHEMBL4721493 0.68 HCAR3 (0.37)
SCHEMBL12076534 0.68 ELANE (0.35)
SCHEMBL16541171 0.67

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109563500-B Azlactone-functionalized substrates for conjugation of biomolecules 罗伯特·博世有限公司 2023-01-24 CN claimed
EP-3464585-B1 AZLACTONE FUNCTIONALIZED SUBSTRATES FOR CONJUGATION OF BIOMOLECULES BOSCH GMBH ROBERT (DE) 2020-03-11 EP claimed
CN-106460232-B Oligonucleotide probe inversion method for in situ synthesized probe array 生捷科技控股公司 2019-12-24 CN claimed
EP-3464585-A1 AZLACTONE FUNCTIONALIZED SUBSTRATES FOR CONJUGATION OF BIOMOLECULES Robert Bosch GmbH (DE) 2019-04-10 EP claimed
WO-2017207298-A1 AZLACTONE FUNCTIONALIZED SUBSTRATES FOR CONJUGATION OF BIOMOLECULES ROBERT BOSCH GMBH (DE) 2017-12-07 WO claimed
US-20170342211-A1 AZLACTONE FUNCTIONALIZED SUBSTRATES FOR CONJUGATION OF BIOMOLECULES ROBERT BOSCH GMBH (DE) 2017-11-30 US claimed
US-20110059501-A1 Protein Glycosylation ISIS INNOVATION LIMITED (GB) 2011-03-10 US claimed
EP-1871784-A2 PROTEIN GLYCOSYLATION ISIS INNOVATION LIMITED (GB) 2008-01-02 EP claimed
WO-2006106348-A2 PROTEIN GLYCOSYLATION ISIS INNOVATION LIMITED (GB) 2006-10-12 WO claimed
US-12528836-B2 Dosing regimens APELLIS PHARMACEUTICALS, INC. (US) 2026-01-20 US disclosed
US-12458695-B2 Dosing regimens and related compositions and methods APELLIS PHARMACEUTICALS, INC. (US) 2025-11-04 US disclosed
US-20250282823-A1 CELL-REACTIVE, LONG-ACTING, OR TARGETED COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS APELLIS PHARMACEUTICALS, INC. 2025-09-11 US disclosed
EP-4585228-A2 DOSING REGIMENS AND RELATED COMPOSITIONS AND METHODS Apellis Pharmaceuticals, Inc. (US) 2025-07-16 EP disclosed
US-20250179130-A1 METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS ON TARGET THERAPEUTICS LLC 2025-06-05 US disclosed
WO-2006012569-A1 POLYMERIC MATERIALS VIA CLICK CHEMISTRY THE SCRIPPS RESEARCH INSTITUTE (US) 2006-02-02 WO disclosed
EP-1613735-A2 EXPANDING THE EUKARYOTIC GENETIC CODE The Scripps Research Institute (US) 2006-01-11 EP disclosed
WO-2005003294-A2 UNNATURAL REACTIVE AMINO ACID GENETIC CODE ADDITIONS THE SCRIPPS RESEARCH INSTITUTE (US) 2005-01-13 WO disclosed
US-20050009049-A1 Expanding the eukaryotic genetic code THE SCRIPPS RESEARCH INSTITUTE (US) 2005-01-13 US disclosed
US-20040265952-A1 protein containing a modified amino acid that carries an azido or alkynyl group for conjugation to a second molecule such as polymer, label or drug that carries an alkynyl or azido group; translation biochemistry in eukaryotic cells; gene expression inhibitors THE SCRIPPS RESEARCH INSTITUTE (US) 2004-12-30 US disclosed
WO-2004094593-A2 EXPANDING THE EUKARYOTIC GENETIC CODE THE SCRIPPS RESEARCH INSTITUTE (US) 2004-11-04 WO disclosed